The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of MDV3100, an androgen receptor signaling inhibitor, on tumor growth of estrogen and androgen receptor-positive (ER+/AR+) breast cancer xenografts.
Anthony D. Elias
No relevant relationships to disclose
Dawn R. Cochrane
No relevant relationships to disclose
Britta M. Jacobsen
No relevant relationships to disclose
Diana M. Cittelly
No relevant relationships to disclose
Erin N. Howe
No relevant relationships to disclose
Annie Jean
No relevant relationships to disclose
Nicole S. Spoelstra
No relevant relationships to disclose
Andrew A Protter
Employment or Leadership Position - Medivation
Stock Ownership - Medivation
Jennifer K. Richer
Consultant or Advisory Role - Medivation
Research Funding - NIH